ALTSTATION.IO

Universal Health Services, Inc. (UHS) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$218.38

Change

+0.88%

Market Cap

$13.90B

Avg Volume

707.0K

Company Overview

Universal Health Services, Inc. (UHS) primarily operates and manages acute care hospitals and outpatient and behavioral health facilities. Their services include a wide range of medical care, such as general and specialty surgeries, internal medicine, emergency care, and various behavioral health services. Their customers are diverse, including patients seeking immediate or ongoing healthcare and healthcare providers relying on their facilities and management services. Established in 1978, UHS is headquartered in King of Prussia, Pennsylvania.

UHS is a market leader in the healthcare sector, particularly in the behavioral health space. They benefit from a broad portfolio that includes both acute care and behavioral health services, giving them an edge in terms of service diversity. Key competitors include HCA Healthcare and Tenet Healthcare, which also operate in the hospital segment. However, the ongoing pressures of regulatory changes and competition for healthcare professionals present significant challenges that could impact future growth.

Currently, UHS is expanding its footprint, showing steady growth in both revenue and operating income. In Q3 2023, they reported a 6% increase in revenues year-over-year, driven largely by demand for their behavioral health services. Recent strategic moves include investments in new facilities and technology to enhance patient care. This focus reflects their commitment to adapt amidst changing healthcare demands and regulatory landscapes.

Key Financials

Market Cap

$13.90B

Revenue

$16.99B

EBITDA

$2.55B

Gross Margin

43.6%

Profit Margin

8.1%

Revenue Growth

13.4%

Total Cash

$112.89M

Total Debt

$5.11B

Free Cash Flow

$839.42M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

10.39

Forward P/E

9.34

Beta

1.27

52-Week High

$246.33

52-Week Low

$152.33

EPS

$21.02

50-Day Avg

$218.46

200-Day Avg

$196.65

Price/Book

1.90

Technical Analysis

Over the past 52 weeks, Universal Health Services, Inc. (UHS) has exhibited a generally upward trend, with a 52-week change of 18.4%, highlighting sustained strength in its performance. Key support is observed around the $180 level, where the stock has rebounded several times throughout the year, while significant resistance is noted around the $220 level, where it has struggled to maintain upward momentum in the end-of-year phase. Notably, the stock formed a series of higher lows and a potential ascending triangle pattern leading into February, suggesting bullish sentiment. In recent weeks, the stock has shown increased momentum, currently trading at $218.38, indicating a re-test of the resistance level after a brief consolidation phase. Currently, this price sits near the upper end of its 52-week range, which suggests that if it can break through resistance, it may have further upside potential; however, a failure to maintain above this level could lead to increased selling pressure.

Recent News and Developments

Here’s a summary of the latest news and developments for Universal Health Services, Inc

(UHS) stock in the past week, covering February 1-7, 2026:

1. Regulatory Scrutiny at Holly Hill Facility

UHS’s Holly Hill facility has again come under regulatory scrutiny following a patient uprising and repeated failures. A report from February 2, 2026, highlighted citations against the facility for issues including the failure to prevent patient-to-patient sexual abuse. This news points to ongoing challenges in maintaining patient safety and regulatory compliance at certain UHS operations.

2. Universal Health Services Schedules Q4 2025 Earnings Release

Universal Health Services, Inc. announced on February 2, 2026, that it would report its fourth-quarter results for the period ended December 31, 2025, after the market closes on Wednesday, February 25, 2026. The company will host a conference call for investors and analysts to discuss these results on Thursday, February 26, 2026, at 9:00 a.m. Eastern time.

Market Sentiment and Analyst Recommendations

Bull Case

UHS trades at a 10.39 P/E with 13.4% revenue growth and a $13.90B market cap that’s cheap relative to its earnings power. The stock is up 18.4% over 52 weeks and currently testing the $220 resistance level, with 17 analysts recommending buy and a median price target of $250.35 — that’s 14.6% upside from current levels. The company is generating $16.99B in revenue, and the valuation multiple leaves room for expansion if the market rotates into healthcare. Cash position of $112.89M provides flexibility, and the ascending triangle pattern suggests momentum could push through resistance. For value investors, the risk-reward at this entry point favors the bulls, especially with earnings coming February 25.

Bear Case

Wells Fargo downgraded UHS to Equal Weight in early January, citing a more challenging hospital environment in 2026 — that’s a meaningful signal from a major bank. The debt load of $5.11B against only $112.89M in cash is a 45-to-1 leverage ratio that limits financial flexibility during downturns. Holly Hill facility failures and regulatory citations around patient safety are operational red flags that could trigger compliance costs and reputational damage. The stock is already near the top of its 52-week range at $218.38, leaving limited upside and significant downside if it fails to break $220 resistance. Market cap dropped 8.2% in the last 30 days despite the stock holding steady, signaling institutional weakness. Hospital margins are under pressure sector-wide, and UHS’s high debt load means earnings pressure flows directly to the bottom line.

What to Watch

The Q4 2025 earnings release on February 25 is the immediate catalyst — watch for margin trends, operating cash flow, and management commentary on 2026 headwinds. Key metrics: operating margin expansion or contraction, same-facility patient volume trends, and debt reduction progress. If the stock breaks above $220 on volume, the next resistance is $246, but failure to hold $220 could trigger a retest of $200. Monitor regulatory updates on Holly Hill and any other facility citations that could signal systemic compliance issues. Track sector-wide hospital admission trends and labor cost inflation, which directly impact UHS’s bottom line. Watch the debt-to-EBITDA ratio closely — if it’s rising, that limits dividend and buyback capacity. The analyst consensus could shift sharply after earnings if management guidance disappoints on 2026 growth.

Analyst Consensus

BUY

Based on 17 analyst opinions

Low Target

$190.00

Mean Target

$250.35

High Target

$302.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Care Facilities

Employees

99,300

Earnings & Dividends

Next Earnings

Feb 25, 2026

EPS (Trailing)

$21.02

Dividend Yield

37.0%

Payout Ratio

3.8%

Frequently Asked Questions

Is UHS a good stock to buy?

Yes, Universal Health Services, Inc. (UHS) is currently rated a BUY by analysts, with a target price of $250.35. Given its solid P/E of 10.39 and forward P/E of 9.34, it presents good value in the healthcare sector.

What is UHS’s price target?

Analysts have set a price target of $250.35 for UHS. This represents an upside potential of about 14.6% from the current price of $218.38.

Does UHS pay a dividend?

Yes, UHS has a robust dividend yield of 37.0%. This attractive yield makes it a compelling option for income-focused investors.

What is the range of UHS’s stock price over the last year?

UHS’s stock price has fluctuated between $152.33 and $246.33 over the past 52 weeks. This range indicates a significant potential for volatility, which investors should consider.

How does UHS compare to other healthcare stocks?

With a market cap of $13.90 billion and strong earnings metrics, UHS is competitively positioned within the healthcare industry. Its P/E and forward P/E ratios suggest that it’s undervalued relative to peers, enhancing its attractiveness.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.